

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Sivaram PILLARISETTI

Conf. No.: 7133

Serial No.: 10/500,769

Case No.: RUS 3.3-014

Filed: January 24, 2005

Examiner: Walter Schlapkohl

Art Unit: 1636

For: METHODS AND COMPOSITIONS FOR
IDENTIFICATION AND THERAPEUTIC USE OF
GENES INVOLVED IN VASCULAR DISEASE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Dear Sir:

This communication is in response to the Office Action mailed on March 21, 2007, setting a one-month period for response that expired on April 21, 2007. Please provide a four-month Extension of Time to answer the Office Action as provided for in 37 CFR 1.136(a). The Examiner has required an election of a single invention group and an election of a single species under 37 CFR 1.143. The Commissioner is authorized to charge any fee that is due to our Deposit Account No.: 50-4237.

Remarks begin on page 2 of this paper.

REMARKS

Claims 1-30 are pending. In the present action, the Examiner has required a restriction of the pending claims into one of two Groups:

- I. Claims 1-13, 18-25, and 27-30 drawn to a method for identifying CMS pathway induced genes and compounds that regulate them.
- II. Claims 14-17 and 26 drawn to a method of diagnosing a vascular or proliferative disease.

Applicants hereby elect to prosecute the subject matter assigned to Group I {i.e., Claims 1-13, 18-25, and 27-30}, without traverse. Applicants expressly reserve the right to pursue the subject matter of the non-elected claims that have been assigned to groups I and III in one or more divisional application(s).

Applicants herein elect to prosecute the following species found in the method of Claim 1 as follows:

The vascular disease stimuli is insulin. The vascular disease marker is IL-6.

Claims 1-3 and 7-9, read on the elected species.

CONCLUSION

Accordingly, Applicant respectfully requests that the Examiner enters the present response to the Restriction Requirement according to the election selected from the grouping presented above.

Respectfully submitted,

By 
Robert Steve Thomas
Reg. No. 52,284

Attorney for Applicants
Reddy US Therapeutics, Inc.
3065 Northwoods Circle
Norcross, GA 30071-1542
Telephone No.: 678-682-9704

Date: August 8, 2007